Clinical Research Directory
Browse clinical research sites, groups, and studies.
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Sponsor: Dizal Pharmaceuticals
Summary
This study will treat patients with CLL/SLL whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.
Official title: A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
155
Start Date
2024-04-29
Completion Date
2028-03
Last Updated
2025-12-01
Healthy Volunteers
No
Interventions
DZD8586
Daily oral dose of DZD8586 at 25 mg.
DZD8586
Daily oral dose of DZD8586 at 50 mg.
DZD8586
Daily oral dose of DZD8586 at 75 mg.
Locations (17)
Research Site
Hefei, Anhui, China
Research Site
Beijing, Beijing Municipality, China
Research Site
Beijing, Beijing Municipality, China
Research Site
Guangzhou, Guandong, China
Research Site
Guangzhou, Guandong, China
Research Site
Zhengzhou, Henan, China
Research Site
Wuhan, Hubei, China
First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Nanjing, Jiangsu, China
Research Site
Changchun, Jilin, China
Research Site
Dalian, Liaoning, China
Research Site
Shenyang, Liaoning, China
Research Site
Jinan, Shandong, China
Research Site
Linyi, Shandong, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Taiyuan, Shangxi, China
Research Site
Tianjin, Tianjin Municipality, China
Research Site
Tianjin, Tianjin Municipality, China